Suppr超能文献

与静脉血栓栓塞相关的新型凝血酶原突变(Arg596Trp,凝血酶原帕多瓦2型)

New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism.

作者信息

Bulato Cristiana, Radu Claudia Maria, Campello Elena, Gavasso Sabrina, Spiezia Luca, Tormene Daniela, Simioni Paolo

机构信息

From the Department of Medicine, Thrombotic and Haemorrhagic Diseases Unit, Veneto Region Hemophilia and Thrombophilia Center, University of Padua Medical School, Padua, Italy.

出版信息

Arterioscler Thromb Vasc Biol. 2016 May;36(5):1022-9. doi: 10.1161/ATVBAHA.115.306914. Epub 2016 Mar 24.

Abstract

OBJECTIVE

Two different prothrombin variants, p.Arg596Leu and p.Arg596Gln, conferring antithrombin resistance to patients with venous thromboembolism have been recently reported. Here, we describe a novel substitution affecting Arg596 of prothrombin molecule (Arginine596 to Tryptophan or p.Arg596Trp or Arg221aTrp in the chymotrypsinogen numbering system or prothrombin Padua 2) in 2 Italian families with venous thromboembolism.

APPROACH AND RESULTS

Prothrombin Padua 2 has been characterized either in plasma of carriers or using Arg596Trp recombinant prothrombin. Routine coagulation tests, thrombin generation, and antithrombin resistance tests were performed, as well as measurement of the levels of thrombin-antithrombin complexes. All carriers were heterozygotes and presented with a mild reduction of the prothrombin activity. Thrombin generation in carriers showed only a markedly prolonged decay. This finding was confirmed in plasma reconstituted with Arg596Trp recombinant prothrombin mimicking a homozygous condition, which showed longer decay and higher endogenous thrombin potential in thrombin generation than wild-type recombinant prothrombin reconstituted plasma. Patient's plasma as well as Arg596Trp recombinant prothrombin showed a clear thrombin resistance to antithrombin inactivation. These findings were supported by the assessment of thrombin-antithrombin complexes formation, which was strongly reduced for Arg596Trp recombinant prothrombin as compared with wild-type recombinant prothrombin. In a series of 400 unrelated consecutive patients with venous thromboembolism, 2 carriers of prothrombin Padua 2 were found (estimated prevalence of 0.5%).

CONCLUSIONS

Our study showed that prothrombin Padua 2 induces antithrombin resistance and is associated with an increased risk of venous thromboembolism. Codon 596 (CGG) of prothrombin is a hot spot for mutations, which constitute a new and relatively frequent cause of inherited thrombophilia.

摘要

目的

最近有报道称,两种不同的凝血酶原变体,即p.Arg596Leu和p.Arg596Gln,会使静脉血栓栓塞患者产生抗凝血酶抗性。在此,我们描述了在两个患有静脉血栓栓塞的意大利家族中,一种影响凝血酶原分子第596位精氨酸(在胰凝乳蛋白酶原编号系统或凝血酶原帕多瓦2中为精氨酸596变为色氨酸或p.Arg596Trp或Arg221aTrp)的新型替代突变。

方法与结果

通过对携带者血浆进行检测或使用Arg596Trp重组凝血酶原对凝血酶原帕多瓦2进行了特征分析。进行了常规凝血试验、凝血酶生成试验和抗凝血酶抗性试验,以及凝血酶 - 抗凝血酶复合物水平的测定。所有携带者均为杂合子,凝血酶原活性略有降低。携带者的凝血酶生成仅显示出明显延长的衰减期。在用模拟纯合状态的Arg596Trp重组凝血酶原重构的血浆中证实了这一发现,与用野生型重组凝血酶原重构的血浆相比,其在凝血酶生成中显示出更长的衰减期和更高的内源性凝血酶潜力。患者血浆以及Arg596Trp重组凝血酶原对凝血酶失活均表现出明显的抗性。凝血酶 - 抗凝血酶复合物形成的评估结果支持了这些发现,与野生型重组凝血酶原相比,Arg596Trp重组凝血酶原的复合物形成显著减少。在一系列400名连续的无亲缘关系的静脉血栓栓塞患者中,发现了2名凝血酶原帕多瓦2的携带者(估计患病率为0.5%)。

结论

我们的研究表明,凝血酶原帕多瓦2会诱导抗凝血酶抗性,并与静脉血栓栓塞风险增加相关。凝血酶原的第596密码子(CGG)是突变热点,这构成了遗传性血栓形成倾向的一个新的且相对常见的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验